Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alligator Bioscience AB ( (SE:ATORX) ) has shared an update.
Alligator Bioscience has been granted a US patent for its bispecific antibody, ATOR-4066, which targets CD40 and CEACAM5. This patent, effective until 2043, strengthens the company’s intellectual property and supports its pipeline of innovative immunotherapies. The patent underscores the company’s commitment to advancing novel cancer treatments and reinforces its position in the immuno-oncology field.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company focused on developing clinical-stage tumor-directed antibody drugs, particularly targeting the CD40 receptor. Their approach aims to enhance T cell priming and counteract the immunosuppressive tumor microenvironment, offering significant potential benefits for cancer patients. The company is listed on Nasdaq Stockholm and is headquartered in Lund, Sweden.
Average Trading Volume: 571,703
Technical Sentiment Signal: Sell
Current Market Cap: SEK143.7M
See more insights into ATORX stock on TipRanks’ Stock Analysis page.